Zanzalintinib

Other namesXL092

Legal status

• Investigational

CAS Number

• 2367004-54-2

PubChem CID

• 139350422

Zanzalintinib

Clinical data
Other names	XL092
Legal status
Legal status	Investigational
Identifiers
IUPAC name 1-N′-(4-Fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
CAS Number	2367004-54-2
PubChem CID	139350422
ChemSpider	114641993
UNII	KC2JC2ZA04
Chemical and physical data
Formula	C29H25FN4O5
Molar mass	528.540 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
InChI InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37) Key:JSPCKALGNNVYOO-UHFFFAOYSA-N

Zanzalintinib (also known as XL092) is an inhibitor of several receptor tyrosine kinases, including VEGFR2, MET, and the TAM kinases AXL and MERTK. It could potentially be used to treat colorectal cancer and renal cell carcinoma (RCC). It is being developed by Exelixis.^[1][2]

STELLAR-303 is a phase 3, randomized trial of zanzalintinib in combination with atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.^[3] The trial found that the combination of zanzalintinib and atezolizumab improved overall survival compared to regorafenib.^[4]

STELLAR-304 (NCT05678673) is a phase 3, randomized trial of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC).^[5]